Back to Journals » Vascular Health and Risk Management » Volume 8

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

Authors Dejager S, Schweizer A, Foley JE

Received 14 March 2012

Accepted for publication 10 April 2012

Published 18 May 2012 Volume 2012:8 Pages 339—348

DOI https://doi.org/10.2147/VHRM.S31758

Review by Single-blind

Peer reviewer comments 3

Sylvie Dejager,1 Anja Schweizer,2 James E Foley3

1Novartis Pharma SAS, Rueil Malmaison, France; 2Novartis Pharma AG, Basel, Switzerland; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Abstract: The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, as monotherapy have been widely confirmed in a large body of clinical studies of up to 2 years’ duration in various populations with type 2 diabetes mellitus. This paper reviews the data supporting the use of vildagliptin in monotherapy. Consideration based on baseline glycated hemoglobin levels and age is given to patient segments where metformin is not appropriate. In addition, although prediabetes is not an indication, this manuscript briefly reviews some of the existing data showing that the mechanisms at work in diabetic populations are active in patients currently classified as prediabetic, with impaired glucose tolerance or impaired fasting glucose. Finally, the rationale for vildagliptin dosing frequency in monotherapy is discussed. In summary, this review aims to define where in community practice the use of vildagliptin as monotherapy is most desirable, focusing on segments of the population with type 2 diabetes mellitus that might receive the greatest benefit from vildagliptin in the management of their disease.

Keywords: vildagliptin, type 2 diabetes, dipeptidyl peptidase-4 inhibitors, monotherapy, elderly

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in patients with peripheral arterial disease

Kunisawa T, Yamagishi A, Suno M, Nakade S, Honda N, Kurosawa A, Sugawara A, Tasaki Y, Iwasaki H

Therapeutics and Clinical Risk Management 2015, 11:107-114

Published Date: 17 January 2015

Dabigatran and myocardial infarction: a foggy scenario

Pontillo D, Patruno N

Vascular Health and Risk Management 2014, 10:45-48

Published Date: 20 January 2014

Endoglin: a critical mediator of cardiovascular health

Kapur NK, Morine KJ, Letarte M

Vascular Health and Risk Management 2013, 9:195-206

Published Date: 6 May 2013

Metabolic biomarkers for predicting cardiovascular disease

Montgomery JE, Brown JR

Vascular Health and Risk Management 2013, 9:37-45

Published Date: 29 January 2013

Comparison of outcome in 1809 patients treated with drug-eluting stents or bare-metal stents in a real-world setting

Vogt A, Schoelmerich A, Pollner F, Schlitt M, Raaz U, Maegdefessel L, Reindl I, Buerke M, Werdan K, Schlitt A

Vascular Health and Risk Management 2011, 7:693-699

Published Date: 22 November 2011

Randomized study to compare valsartan ± HCTZ versus amlodipine ± HCTZ strategies to maximize blood pressure control

Dion Zappe, Cheraz Cherif Papst, Philippe Ferber, et al.

Vascular Health and Risk Management 2009, 5:883-892

Published Date: 22 October 2009